LLY
Price
$1151.25
Change
-$37.47 (-3.15%)
Updated
Oct 8, 11:11 AM (EDT)
Capitalization
1.06T
21 days until earnings call
Intraday BUY SELL Signals
NVS
Price
$141.59
Change
-$1.68 (-1.17%)
Updated
Oct 8, 11:13 AM (EDT)
Capitalization
278.08B
19 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LLY vs NVS

LLY vs NVS Comparison Chart in %
View a ticker or compare two or three
VS
LLY vs. NVS commentary
Oct 08, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LLY is a Hold and NVS is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
LLY vs NVS: Fundamental Ratings
LLY
NVS
OUTLOOK RATING
1..100
3666
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
910
SMR RATING
1..100
1433
PRICE GROWTH RATING
1..100
4361
P/E GROWTH RATING
1..100
5821
SEASONALITY SCORE
1..100
3150

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (4) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (52). This means that NVS’s stock grew somewhat faster than LLY’s over the last 12 months.

LLY's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is in the same range as NVS (10). This means that LLY’s stock grew similarly to NVS’s over the last 12 months.

LLY's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as NVS (33). This means that LLY’s stock grew similarly to NVS’s over the last 12 months.

LLY's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as NVS (61). This means that LLY’s stock grew similarly to NVS’s over the last 12 months.

NVS's P/E Growth Rating (21) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (58). This means that NVS’s stock grew somewhat faster than LLY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LLYNVS
RSI
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
50%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
57%
Momentum
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
49%
MACD
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
54%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
40%
Advances
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 11 days ago
54%
Declines
ODDS (%)
Bearish Trend 7 days ago
55%
Bearish Trend 3 days ago
45%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
35%
Aroon
ODDS (%)
Bearish Trend 2 days ago
74%
N/A
COMPARISON
Comparison
Oct 08, 2026
Stock price -- (LLY: $1188.72 vs. NVS: $143.28)
Brand notoriety: LLY: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: LLY: 91% vs. NVS: 92%
Market capitalization -- LLY: $1.06T vs. NVS: $278.08B
LLY [@Pharmaceuticals: Major] is valued at $1.06T. NVS’s [@Pharmaceuticals: Major] market capitalization is $278.08B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.06T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $200.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LLY’s FA Score shows that 2 FA rating(s) are green while NVS’s FA Score has 4 green FA rating(s).

  • LLY’s FA Score: 2 green, 3 red.
  • NVS’s FA Score: 4 green, 1 red.
According to our system of comparison, NVS is a better buy in the long-term than LLY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LLY’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 5 bullish TA indicator(s).

  • LLY’s TA Score: 6 bullish, 3 bearish.
  • NVS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, LLY is a better buy in the short-term than NVS.

Price Growth

LLY (@Pharmaceuticals: Major) experienced а +2.73% price change this week, while NVS (@Pharmaceuticals: Major) price change was +0.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -3.85%. For the same industry, the average monthly price growth was -6.67%, and the average quarterly price growth was +4.54%.

Reported Earning Dates

LLY is expected to report earnings on Oct 29, 2026.

NVS is expected to report earnings on Oct 27, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (-3.85% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
LLY
Daily Signal:
Gain/Loss:
NVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IPM1.770.06
+3.51%
Intelligent Protection Management Corp
TG7.160.13
+1.85%
Tredegar Corp
SPHR106.240.86
+0.82%
Sphere Entertainment Co
AIIR7.77-0.15
-1.89%
Air Global Plc
NXPI235.22-9.16
-3.75%
NXP Semiconductors NV

LLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, LLY has been loosely correlated with JNJ. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then JNJ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LLY
1D Price
Change %
LLY100%
+2.70%
JNJ - LLY
45%
Loosely correlated
+1.44%
NVS - LLY
43%
Loosely correlated
+1.77%
GSK - LLY
42%
Loosely correlated
+0.90%
BMY - LLY
41%
Loosely correlated
+0.18%
PFE - LLY
39%
Loosely correlated
+1.82%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+1.77%
GSK - NVS
59%
Loosely correlated
+0.90%
JNJ - NVS
51%
Loosely correlated
+1.44%
BMY - NVS
50%
Loosely correlated
+0.18%
ABBV - NVS
48%
Loosely correlated
+1.75%
MRK - NVS
47%
Loosely correlated
+0.60%
More